Update on cytokines as novel cancer immunotherapy
In this post, it’s time to put your thinking caps on and empty your minds of any pre-conceived bias in order to play the modern version of Star Trek tridimensional chess aka IO combination trials.
Here we weave now together some important themes and highlight intriguing ideas that at first seem dissimilar, but actually have much more in common than many realise.
Data from bone chillingly cold poster halls of conferences in the distant past can come back and reviewed afresh in the light of new developments. The seasoned observer discards neither these findings or thought leader snippets of insights within nor forgets them in an instant, as many do after the hum of instant live reactions passes.
With oncolytic viruses and cytokines being much in the news of late, what can we learn about where things are likely headed?
To get a heads up on our latest oncology insights and commentary including sentiments from though leaders, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers